Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Immune checkpoints blockade (ICB) is a viable anti-cancer strategy. Here the authors show that nuclear receptor NR2F6 acts as an immune checkpoint in T cells and, using mouse models and human T cells, they show NR2F6 inhibition might improve current ICB therapy or work as an alternative therapeutic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Victoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, Bojana Jakic, Anne Offermann, Mirjana Efremova, Sieghart Sopper, Dietmar Rieder, Anne Krogsdam, Gabriele Gamerith, Sven Perner, Alexandar Tzankov, Zlatko Trajanoski, Dominik Wolf, Gottfried Baier
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6708fd1e3e99478a95dc46aa8093f81c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Immune checkpoints blockade (ICB) is a viable anti-cancer strategy. Here the authors show that nuclear receptor NR2F6 acts as an immune checkpoint in T cells and, using mouse models and human T cells, they show NR2F6 inhibition might improve current ICB therapy or work as an alternative therapeutic strategy.

Ejemplares similares